Research programme: mixed neurotransmitter receptor antagonists - SK biopharmaceuticals
Latest Information Update: 28 Sep 2011
At a glance
- Originator SK Holdings
- Developer SK biopharmaceuticals
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists; Sigma receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Psychiatric disorders; Psychotic disorders
Most Recent Events
- 28 Sep 2011 Preclinical development is ongoing in South Korea
- 10 Apr 2008 Preclinical trials in Psychiatric disorders in South Korea (unspecified route)
- 10 Apr 2008 Preclinical trials in Psychotic disorders in South Korea (unspecified route)